Cytokinetics Announces Continuation of COURAGE-ALS Following First Interim Analysis
Phase 3 Clinical Trial to Proceed to Second Interim Analysis Expected to Occur in 2023SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022...
Staff
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
First Genetically Modified (TALEN®-edited) Iovance TIL Therapy with Inactivated PD-1 Expression SAN CARLOS, Calif., Oct. 10, 2022 (GLOBE NEWSWIRE) --...
First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360
Poster presentation indicates new microgranule formulation elicited desired delayed release profile, offering protection at acidic pH and rapid release under...
Zynerba Pharmaceuticals Announces Poster Presentation at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit
DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing...
Microbot Medical Receives Patent Allowance in Israel for the LIBERTY® Robotic System
Complements Existing Allowance in the U.S. as Global Jurisdictions Recognize the Uniqueness of the TechnologyHINGHAM, Mass., Oct. 10, 2022 (GLOBE...
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas
Clinical and pre-clinical data from across the company’s portfolio will be featured in four oral and six poster presentations Co-founder...
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that...
HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM;...
eureKARE to host SynBio Day 2022 entitled ‘Synthetic Biology for the Protection of our Planet’
eureKARE to host SynBio Day 2022 entitled‘Synthetic Biology for the Protection of our Planet’ To be held 13-14 October in...
Press news Biocartis Group NV: Biocartis Initiates Commercialization in Europe of HepatoPredict (CE-IVD) Test for Liver Cancer Patients
PRESS RELEASE: 10 October 2022, 07:00 CEST Biocartis Initiates Commercialization in Europe of HepatoPredict (CE-IVD) Test for Liver Cancer PatientsHepatoPredict helps...
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientific Conferences
Saint-Herblain (France), October 10, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announces today it...
Santhera and ReveraGen Announce Presentations on Long-Term Efficacy and Bone Health in DMD During Vamorolone Treatment at the 2022 World Muscle Society Congress
Pratteln, Switzerland, and Rockville, MD, USA, October 10, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of...
The Well Lounge Med Spa Announces the Launch of Their New Website
The Newtown-Based Med Spa Is Pleased to Announce That Their New Site Has Gone LiveNEWTOWN, Pa., Oct. 07, 2022 (GLOBE...
Agra Ventures Grants Restricted Share Units
VANCOUVER, British Columbia, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Agra Ventures Ltd. (“AGRA” or the “Company”) (CSE: AGRA) (OTC: AGFAF),...
RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals to address unmet needs in oncology; Michael Lee-Chin appointed to the board of the company
HOUSTON and BURLINGTON, Ontario, Oct. 07, 2022 (GLOBE NEWSWIRE) -- RadioMedix, Inc. (“RadioMedix” or “Company”), a clinical-stage biotechnology company announced...
XORTX Announces Closing of US$5 Million Public Offering
CALGARY, Alberta, Oct. 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX...
ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic
SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038...
PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value
Topics to Include Continued Analysis of FDA’s Clinical Hold on IND for Cell-in-a-Box®LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte...